A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 1, 2006, Pages 3-7

  Tinker, Anna ^a   Winquist, Eric ^b   Canil, Christina ^c   Moore, Malcolm ^c   Murray, R Nevin ^a   Chi, Kim N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Advanced urothelial transitional cell carcinoma; Combination chemotherapy; Phase I trial; Weekly docetaxel

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEATH; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRY SKIN; EDEMA; EYE IRRITATION; FATIGUE; FEMALE; FEVER; HEADACHE; HEARING DISORDER; HUMAN; INSOMNIA; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TAXOIDS; URINARY BLADDER NEOPLASMS;

EID: 33644859154     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000200044.81711.57     Document Type: Article

References (24)

1. Jemal A, Thomas A, Murray T, et al. Cancer Statistics. CA Cancer J Clin. 2002;52:23-47.
2. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin, in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-1073.
3. Saxman SB, Propert KJ, Einhron LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin, in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
4. Moore M, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876-2881.
5. Dreicer R, Manola J, Roth BJ, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2000;18:1058-1061.
6. Redman BG, Smith DC, Flaherty L, et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 1998;16:1844-1851.
7. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized multinational, multicentre, phase III study. J Clin Oncol. 2000;18:3068-3077.
8. Bamais A, Aravantinos G, Deliveliotos C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicentre, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220-228.
9. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitibine is an active treatment for advanced urothelial cancer. Updated results. J Clin Oncol. 2001;19:2527-2533.
10. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitibine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol. 2000;18:3247-3255.
11. Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol. 2002;13:243-250.
12. Hovey EJ, Owen CE, Shelton GB, et al. Phase I/II study of docetaxel (D), gemcitibine (G), carboplatin (C) in poor prognosis and previously treated patients (Pts) with urothelial carcinoma (UTC) (abstract 1376). Proc Am Soc Clin Oncol. 2000;19:350a.
13. Hainsworth JD, Burris HA, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
14. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol. 1999;26(suppl 11):28-31.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
16. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (TAXOL). Semin Oncol. 1993;20(suppl 3):1-15.
17. Akerley W 3rd, Glantz M, Choy H. Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol. 1996;23(suppl 12):14-18.
18. Ravdin P, Reban J, Overmoyer B, et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer. Eur J Cancer Suppl. 2003;1:S201.
19. Poole CJ, Hogberg T, Perren T, et al. A phase I trial of gemcitabine day 1 and 8 and paclitaxel/3 hrs infusion day 8 (or day 1), in patients with recurrent epithelial ovarian cancer (EOC) after one prior platinum regimen. Ann Oncol. 1998;9:390.
20. Rowinsky EK, Gilbert MR, McGuirre WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991;9:1692-1703.
21. Kroep JR, Peters GJ, van Moorsel CJ, et al. Gemcitabine-cisplatin: a schedule finding study. Ann of Oncol. 1999;10:1503-1510.
22. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966-1972.
23. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000;18:2537-2544.
24. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.